Navigation Links
Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
Date:5/8/2008

VYVANSE demonstrated significant improvement in ADHD symptoms in adults

WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints.

"Adults with ADHD often find it challenging to focus and organize during the day. The disorder may impact many aspects of their lives from career to family and personal commitments," said Lenard A. Adler, M.D., lead researcher in this study and director of the Adult ADHD program at the NYU Langone Medical Center, associate professor of psychiatry, neurology and child and adolescent psychiatry at the New York University School of Medicine, as well as author of Scattered Minds: Help and Hope for Adults with ADHD (G. P. Putnam's Sons 2006). "This study demonstrated that VYVANSE significantly improved ADHD symptoms in adults, including inattention, such as the ability to focus, organize and complete tasks, which are essential during an adult day, as well as hyperactivity, such as restlessness, and impulsivity."

This double-blind, placebo-controlled, four-week, forced-dose study in 414 adults aged 18 to 55 years showed that treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) provided a significant reduction in ADHD Rating Scale (ADHD-RS-IV) scores within one week that were observed throughout the full treatment period. At endpoint, VYVANSE demonstrated a significant improvement in ADHD symptoms, based on a 43 percent reduction in ADHD-RS scores. This is the largest placebo-controlled stimulant trial of ADHD in adults conducted to date.

Additional Study Findings

Investigators also measured the efficacy of VYVANSE with the Clinical Global Impressions-Improvement (CGI-I) scale and found that the percent
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/13/2008)... III Trial Experience Better, Long-Term Clinical O...ents Treated with TAXUS,...-- Long-term data,presented for the first time tod...l trial studying the XIENCE(TM) V Everolimus Eluti... V continues to deliver clinically superior,benefi...
(Date:5/13/2008)... the Treatment of Inflammatory ...n Payment from Partner GlaxoSmithKline, MOUNTAIN ... Inc., today,announced the initiation of a Phase I...vel small molecule compound designed to specifical...ociated with inflammatory,diseases such as rheumat...
(Date:5/13/2008)...soluble polymer material,designed to stop bone ble...,according to a new animal study just published in...s come on the heels of recently published,research... the risk of,surgical infections., Researchers fr...rleston,and Keck School of Medicine at the Univers...
(Date:5/12/2008)...ion Prevention Business, DUBLIN, Ohio, May 12 /PR...rovider of products and services that improve the ...unced it has completed the,acquisition of assets o...f,infection prevention products sold under the Chl...cts are used widely in U.S. hospitals and,surgery ...
Breaking Medicine Technology:XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 2XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 3XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 4XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years 5ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 2Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 3Cardinal Health Completes Enturia Acquisition 2Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 109 1Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 109 2Green Tea May Brew Up Healthier Skin 106 1Third Security LLC Hires Two New Managing Directors 110 1Third Security LLC Hires Two New Managing Directors 110 2Web Portal Makes Organ Donation Easy 108 1Web Portal Makes Organ Donation Easy 108 2
(Date:5/13/2008)...exercise helps prevent the disease, two additional...(HealthDay News) -- New research has found both ba...The bad news is a risk factor you can,t change: Wo...r face an increased risk of breast cancer througho...t diagnosis, according to a study in the May 13 is...
(Date:5/13/2008)...gress in patient safety research could slow to a c...issues, Johns Hopkins researchers assert in an upc...paradigm to patient safety research. It just isnt ...ctor for public health at the Johns Hopkins Berman...le. , The piece, published in the June issue of ...
(Date:5/13/2008)...mWater kicks off the summer with SYNERGY Events, ,...ve makeover competition, BOSTON, May 13 /PRNewswi... SYNERGY Events, the premier event planning compan...al live makeover competition. The,competition will...ns on May,16, 2008. Doors open at 8:30 p.m. at the...
(Date:5/13/2008)...AN ANTONIO, Texas, May 13 /PRNewswire/ -- Attorney...list Mormon community in Eldorado, TX,will ask a ...rgency order,to prevent the state from taking away... turns a year old on Thursday., Attorneys are fil...m.,seeking an emergency injunction to keep the Tex...
Breaking Medicine News(10 mins):Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 2Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 3Health News:Treating safety research like other clinical studies slows progress 2Health News:Treating safety research like other clinical studies slows progress 3Health News:TrimWater Keeps Boston Beautiful 2Health News:TrimWater Keeps Boston Beautiful 3Health News:FLDS Couple Seeks Emergency Order to Stop Infant Seizure, Say Perry & Haas 2Health News:FLDS Couple Seeks Emergency Order to Stop Infant Seizure, Say Perry & Haas 3
...ity of Texas feel that they may have found an effe...mor that threatens clear vision.// Using photodyna...ion in three patients who were suffering from intr...nvolved serious retinal detachments. Intraocular c...
...rom the University of California, they have observ...at a higher risk for developing Osteoarthritis. Os... causes pain in that area.// Osteoarthritis affect...s old. Experts estimate up to 70 percent of women ...
...hildren and teens with chronic fatigue syndrome ar...flexible joints than their healthy counterparts.//...in Baltimore examined 100 children, ages 10 and ol... evenly between patients diagnosed with CFS and ot...
...vely controlled with a higher dose of radiotherap...t for lung cancer involves a daily dose of radioth...r results have been found from a more intensive pr...ay for 12 days. Now researchers at the Mount Verno...
Other Medicine News:
Clearview Strep A Exact uses rapid technology to provide direct detection of Group A Streptococcal antigen from throat swabs. , ,Clearview Strep A Exact uses a patented, innovative technology to
One inch disposable patch electrode uses a specially formulated adhesive solid gel. Reusable lead wire with snap connector provides economic benefits. Ideal for sleep studies where leg movement or EK
Made with elastic fabric, these head cap systems are packaged to provide everything you need to begin testing. Each Electro-Cap System features pure tin electrodes positioned according to the Interna
Made with elastic fabric, these head cap systems are packaged to provide everything you need to begin testing. Each Electro-Cap System features pure tin electrodes positioned according to the Interna
Medicine Products: